E-resources
-
Takashima, Atsuo; Shitara, Kohei; Fujitani, Kazumasa; Koeda, Keisuke; Hara, Hiroki; Nakayama, Norisuke; Hironaka, Shuichi; Nishikawa, Kazuhiro; Kimura, Yutaka; Amagai, Kenji; Fujii, Hirofumi; Muro, Kei; Esaki, Taito; Choda, Yasuhiro; Takano, Toshimi; Chin, Keisho; Sato, Atsushi; Goto, Masahiro; Fukushima, Norimasa; Hara, Takuo; Machida, Nozomu; Ohta, Manabu; Boku, Narikazu; Shimura, Masashi; Morita, Satoshi; Koizumi, Wasaburo
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 01/2019, Volume: 22, Issue: 1Journal Article
Background In the ABSOLUTE trial, weekly nanoparticle albumin-bound paclitaxel (w-nab-PTX) showed non-inferiority to weekly solvent-based paclitaxel (w-sb-PTX) for overall survival (OS). Thus, w-nab-PTX might be an option for second-line chemotherapy in advanced gastric cancer (AGC). However, predictive factors for efficacies of these agents have not been evaluated. Methods Patients previously enrolled in the ABSOLUTE trial were divided into apparent peritoneal metastasis group (PM group) and no apparent peritoneal metastasis group (no PM group) based on baseline imaging evaluated by RECIST ver. 1.1 criteria and amount of ascites. OS, progression-free survival, and overall response rate were compared between two arms in each group. Results This study included 240 and 243 patients in the w-nab-PTX and w-sb-PTX arms, respectively. In the PM group, the w-nab-PTX arm ( n = 88) had longer OS than the w-sb-PTX arm ( n = 103), and median survival time (MST) of 9.9 and 8.7 months hazard ratio (HR) 0.63; 95% CI 0.45–0.88; P = 0.0060, respectively. In the no PM group, the w-nab-PTX arm ( n = 140) had shorter OS than the w-sb-PTX arm ( n = 152), and MST of 11.6 and 15.7 months (HR 1.40; 95% CI 1.06–1.86; P = 0.0180), respectively. After adjusting for prognostic factors, the HR for OS in the w-nab-PTX arm versus the w-sb-PTX arm was 0.59 (95% CI 0.42–0.83; P = 0.0023; PM group) and 1.34 (95% CI 1.01–1.78; P = 0.0414; no PM group), with significant interaction between treatment efficacy and presence of peritoneal metastasis ( P = 0.0003). Conclusions The presence of apparent peritoneal metastasis might be a predictive factor for selecting w-nab-PTX for pretreated AGC patients. Trial registration number JapicCTI-132059.
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.